- Clearmind Medicine Inc. (CMND) announced on **October 21, 2025**, the enrollment of the **last patient for the first cohort** of its FDA-Approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD).  **[1892500_0001213900-25-100535_ea026193002ex99-1_clearmind.htm:0]** 
- The trial is evaluating **CMND-100**, the company's proprietary MEAI-based oral drug candidate.  **[1892500_0001213900-25-100535_ea026193002ex99-1_clearmind.htm:0]** 
- **Six patients** were successfully enrolled in this initial cohort at Johns Hopkins University School of Medicine and Yale School of Medicine’s Department of Psychiatry.  **[1892500_0001213900-25-100535_ea026193002ex99-1_clearmind.htm:0]** 
- Clearmind Medicine anticipates sharing **topline data from the first cohort** and plans to activate two additional sites in Israel to maintain or improve the pace of enrollment.  **[1892500_0001213900-25-100535_ea026193002ex99-1_clearmind.htm:0]**

Clearmind Medicine completes enrollment for first cohort of Phase I/IIa AUD clinical trial

- Clearmind Medicine Inc. has entered into securities purchase agreements with institutional investors, allowing the company to issue and sell convertible promissory notes for an aggregate principal amount of up to **$10,000,000**.  **[1892500_0001213900-25-089237_ea025802902ex99-1_clearmind.htm:0]** 
- On **September 19, 2025**, the company completed its first initial closing, issuing notes with a principal amount of **$555,556** for a purchase price of **$500,000**.  **[1892500_0001213900-25-089237_ea025802902ex99-1_clearmind.htm:0]** 
- The net proceeds from these notes are designated for **working capital, general corporate purposes, and potential acquisitions** to explore strategic opportunities.  **[1892500_0001213900-25-089237_ea025802902ex99-1_clearmind.htm:0]**

Clearmind Medicine Secures $10 Million Securities Purchase Agreement

- Clearmind Medicine Inc. reported a **net loss** of **$1,313,592** for the three months ended **July 31, 2025**, and **$3,169,141** for the nine months ended **July 31, 2025**.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:4]** 
- As of **July 31, 2025**, the company held **$3,495,338** in cash and cash equivalents and had **$918,215** in working capital.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:6]** 
- The company initiated its **Phase I/IIa clinical trial** for CMND-100 in Alcohol Use Disorder (AUD) in Israel in **March 2025** and in the U.S. in **April 2025**, with the first patient dosed in **June 2025** at Yale School of Medicine.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:2]** 
- On **December 16, 2025**, Clearmind announced signing a non-binding term sheet with Dr. Glitter Pty Ltd for the development and commercialization of a MEAI-based alcohol substitute.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:2]** 
- The company anticipates its current cash and cash equivalents will provide sufficient liquidity for at least **twelve months**, though additional financing may be required to advance all its programs.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:6]**

Clearmind Medicine (CMND)